Co-led $65M Series A for Dualitas Therapeutics to advance bispecific antibodies for immune and inflammatory disease.
Dualitas Therapeutics is a biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies for immunology and inflammation (I&I)
Dualitas Therapeutics is a biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies for immunology and inflammation (I&I). The company utilizes its proprietary DualScreen™ Bispecific Discovery Engine to discover novel bispecific antibody candidates with differentiating biology, including through cell-surface proximity mechanisms.